06.23.25 -- The Promise And Challenges Of Cell-Free Protein Systems

Perfusion cell culture technology supports high cell densities and product yields for viral vaccine manufacturing, offering a reliable way to produce high-quality cells at a commercial scale.

A new chemically defined fed-batch bioprocess medium simplifies hMSC-EV production, increasing yields by 2-4x while maintaining EV quality across donors and tissue types in scalable environments.

To execute complex viral product manufacturing, a service provider needs expertise in adherent cell culture capabilities, cell line productivity, and the intricacies associated with these products.

Researchers developed base-edited CAR T cells and CD45-edited stem cells to create universal blood cancer immunotherapy, showcasing efficacy while minimizing toxicity using electroporation technology.

Unlocking the potential of next-generation therapeutics requires extending the boundaries of both expression system technology and process development and manufacturing.

Scaling up life-saving gene-edited cell therapies means tackling production inefficiencies. Overcoming the time-consuming and risky cell washing step is crucial for clinical and commercial success.

Find out how you can simplify the process of media design and customization, reduce cost, and facilitate sustainable science with high quality GMP products.

Explore critical environmental and economic aspects of bioprocessing, like the urgent need to manage the industry’s growing plastic waste issue and a three-pronged approach to address this challenge.

Unlock the potential of perfusion for pluripotent stem cell cultures. Explore key insights into achieving improved consistency and quality in your medium exchange protocols, leading to better outcomes.